Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)‘s stock had its “hold” rating reissued by equities researchers at Piper Jaffray Companies in a note issued to investors on Friday. They presently have a $45.00 price target on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ target price points to a potential downside of 7.41% from the company’s current price.

A number of other research analysts also recently issued reports on SUPN. Cowen and Company boosted their price objective on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, May 11th. Cantor Fitzgerald boosted their price objective on Supernus Pharmaceuticals from $25.00 to $27.00 and gave the company an “overweight” rating in a research note on Thursday, May 11th. Jefferies Group LLC boosted their price objective on Supernus Pharmaceuticals from $35.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, May 31st. BidaskClub upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Finally, Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective for the company in a research note on Thursday, July 13th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Supernus Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $48.29.

Shares of Supernus Pharmaceuticals (SUPN) traded up 1.67% during midday trading on Friday, hitting $48.60. 806,019 shares of the stock were exchanged. Supernus Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $49.95. The firm’s 50 day moving average price is $43.51 and its 200-day moving average price is $36.73. The stock has a market cap of $2.46 billion, a P/E ratio of 24.52 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.08. The business had revenue of $75.83 million during the quarter, compared to the consensus estimate of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. On average, equities research analysts expect that Supernus Pharmaceuticals will post $1.04 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Supernus Pharmaceuticals, Inc. (SUPN) Given “Hold” Rating at Piper Jaffray Companies” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/09/supernus-pharmaceuticals-inc-supn-given-hold-rating-at-piper-jaffray-companies.html.

In related news, VP Padmanabh P. Bhatt sold 3,735 shares of the business’s stock in a transaction that occurred on Wednesday, July 12th. The stock was sold at an average price of $44.90, for a total value of $167,701.50. Following the transaction, the vice president now directly owns 21,209 shares of the company’s stock, valued at approximately $952,284.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Padmanabh P. Bhatt sold 3,709 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $45.23, for a total value of $167,758.07. Following the completion of the transaction, the vice president now directly owns 17,500 shares in the company, valued at $791,525. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,000 shares of company stock valued at $450,224. 6.70% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Pinebridge Investments L.P. lifted its holdings in Supernus Pharmaceuticals by 1.3% in the 2nd quarter. Pinebridge Investments L.P. now owns 6,624 shares of the specialty pharmaceutical company’s stock worth $285,000 after purchasing an additional 86 shares in the last quarter. Louisiana State Employees Retirement System lifted its holdings in Supernus Pharmaceuticals by 0.5% in the 2nd quarter. Louisiana State Employees Retirement System now owns 20,500 shares of the specialty pharmaceutical company’s stock worth $884,000 after purchasing an additional 100 shares in the last quarter. Arizona State Retirement System lifted its holdings in Supernus Pharmaceuticals by 0.4% in the 2nd quarter. Arizona State Retirement System now owns 26,201 shares of the specialty pharmaceutical company’s stock worth $1,129,000 after purchasing an additional 100 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Supernus Pharmaceuticals by 0.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,650 shares of the specialty pharmaceutical company’s stock worth $1,579,000 after purchasing an additional 128 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its holdings in Supernus Pharmaceuticals by 3.2% in the 1st quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock worth $173,000 after purchasing an additional 170 shares in the last quarter. 95.38% of the stock is currently owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.